血压控制与脑出血治疗和预防课件.ppt
- 【下载声明】
1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
3. 本页资料《血压控制与脑出血治疗和预防课件.ppt》由用户(三亚风情)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 血压 控制 脑出血 治疗 预防 课件
- 资源描述:
-
1、血压控制 与 脑出血治疗和预防北京大学第一医院神经科黄一宁教授Primary Intracerebral Haemorrhage10-15% all strokes (Caucasians)20-30% in Asian/AfricanPathology (80-90% of all ICH) Hypertensive angiopathy Amyloid angiopathySitesBasal Ganglia Putamen (40%), thalamus (15%), caudate (5-10%)Cerebellum (10%), pons (10%)Lobar (10-20%)Hae
2、matoma evolutionEarly haematoma expansionOnset-CT interval (h)ProspectiveRetrospectiveBrottFujiiKazuiTakizawa 0-338%18%36%17% 3-6N/A8%16%6% 6-24N/A2%10%0%Peri-haematomal oedema in ICH Precise aetiology unclear cytotoxic vs vasogenic Is there a peri-haematomal ischaemic penumbra? Rational acute BP lo
3、wering requires better understanding of peri-haematomal oedemaSurgical treatmentSTICH trial resultsMedical treatmentrFVII (NovoSeven)Mayer et al. NEJM 2005; 352: 777-85Reduction of haematoma expansionMayer et al. NEJM 2005; 352: 777-85北大医院临床诊治方案Role of blood pressureobservational studies - mortality
4、SBP (mm Hg)1 month mortality (%)FogelholmVemmosOnset of ICH3-6 6-12 hours12hrs to one week1-4 weeksmonthsBP loweringhaemorrhagerebleedingoedemastroke recurrence拉贝洛尔labetalol 5100mg/h, 间断注入,每次1040mg,或者 连续点滴 28mg/min 我国药典禁忌在脑出血使用拉贝咯尔 艾司洛尔esmolol 负荷量500mcg/kg;维持量 50200 mcg.kg-1min 硝普钠 nitroprusside 0.5
5、-10 mcg.kg-1min-1 尼卡地平 nicardipine 5mg/h, 每15分钟增加 2.5mg/h, 最大量为15mg/h 肼苯哒嗪 hydralazine 10-20mg, q4-6h 依那普利 0.625-1.2 mg q6h, 根据需要调节剂量Guidelines for Acute BP ManagementStart medicationTargetICHAHA (1999) 180/105 mm Hg 180/105 mm Hg ISH (2003) 180/105 mm Hg 180/105 mm HgNZ (2003)Mean BP 130 mm HgMean
6、BP 220/120 mm Hg180/100-105 mm Hg (HT) 160-180/90-105 mm Hg (non-HT)UK (2004)if complications are apparentNot describedINTERACT pilot phase(Lancet Neurology 2008; 7: 391-399.)PathophysiologyElevated Blood PressureOngoing bleedingRe-bleedingHaematoma sizePoor outcomeCerebral oedema Vanguard PhaseProt
7、ocol SchemaRandomisationAcute ICH - onset within 6 hoursSBP 150 and 220 mmHgRepeat CT scans 24 + 72 hrsVital signs and BP over 7 days28 day and 3 month follow-upIntensive BP loweringTarget SBP 140mmHgGuideline-based BP managementTarget SBP 180 mmHgSystolic blood pressure differencesMean systolic BP
8、over time including 95% CITimeMean BP130140150160170180190Systolic BP: ControlSystolic BP: TreatmentTime 0Time 115min30min45min1hr6hr12hr18hr24hrday2amday2pmday3amday3pmday4amday4pmday5amday5pmday6amday6pmday7amday7pmday28amday28pmCrude mean (SD) change in hematoma volume by groupVolume (ml)Guidelin
9、e groupIntensive groupBaseline24 hours12.715.414.215.2 Clinical outcomes at 90 daysStandard(n = 201)Intensive(n = 203)pDeath or dependency49480.81Death12100.51Dependency41360.98Modified Rankin Score, median 2 20.66NIHSS, median220.97Barthel Index score, median95950.77MMSE, median28270.97EuroQoL, EQ5
10、D, median, %78750.97Early intensive blood pressure lowering enhances hematoma resolution but does not affect perihematoma edema:Yining HuangPeking University First Hospital, Beijing, ChinaOn behalf of C Anderson, Q Li, E Heeley, B Peng, C Skulina, J Wang, for the INTERACT Investigators Secondary aim
11、sTo determine the effects of early intensive blood pressure lowering treatment on hematoma and perihematoma edema growth over 72 hoursSecondary analyses: patient flow404 Patients randomized201 Guideline-based BP lowering145 in hematoma analysis1 Patient not ICH151 in hematoma analysis131 in edema an
12、alysis139 in edema analysis14 Unable to estimate edema volume12 Unable to estimate edema volume56 Missing CT data at 24h and/or 72h51 Missing CT data at 24h and/or 72h203 Early intensive BP loweringMean BP after randomization2000 15 30 45 60 612 18 241501005023456728 90MinutesHoursDaysMean blood pre
13、ssure (mm Hg)GuidelineIntensiveSBP 14 mm Hg at 1 hour (P0.0001)SBP 12 mm Hg from 1-24 hours (P0.0001)SBP 11 mm Hg from 1-3 days (P Early intensive BP lowering treatment lowered systolic BP by 10 mm Hg was associated with reduction in absolute (-2.8ml; P=0.002) and relative (-10%; P=0.04) increase in
14、 hematoma volume over 72 hoursPerihematoma edema analysis Early intensive BP lowering had no clear effects on absolute or relative increase in perihematoma edema volume over 72 hoursYN Huang, C Yan, W Jiang, et al Lancet Neurology 2008, May阿司匹林已经成为公认的缺血性卒中二级预防首选药物Guidelines for prevention of stroke
15、in patients with ischemic stroke or TIAs, Stroke, 2006;37:577-617AHA/ACC guidelines for secondary prevetion for patients with coronary and other atherosclerotic vascular disease: 2006 update, JACC 2006; 47( 10),2130 NATURE REVIEWS - DRUG DISCOVERY VOLUME 2; OCTOBER 2003; 1-15Stronger Inhibition of P
16、latelets: Stronger Inhibition of Platelets: Combine different PathwaysCombine different Pathways+Aspirin + ClopidogrelAspririn + placebo 0 3 6 9 12P0.0010.140.120.100.080.060.040.020.00Months of Follow-upCumulative Hazard Rate Vascular Death + MI+ Strokeafter 4 weeks and after 4.5 MonthAdded Benefit
17、 of Clopidogrel to ASA treatment in Unstaible Angina Patients RRR: 6.4% (95% CI: - 4.6% 到到 16.3%)(p=0.244) ASA + 氯吡格雷氯吡格雷 (15.7%) 安慰剂安慰剂 + 氯吡格雷氯吡格雷 (16.7%)IS、MI、VD、因急性缺血事件再住院、因急性缺血事件再住院累积事件率0.000.040.080.120.160.20随访月数 0 3 6 9121518ARR: 1.0% Lancet 2004; 364: 331-37N=7599 1-1.5年 Defined as recent IS
18、 or TIA with previous ischemic event or diabetesN Engl J Med 2006,354:10 6 12 18 24 301086420月Accumulation of events()aspirinclopidogrel plus aspirinP=0.22N Engl J Med 2006,354:1Endpoints: MI, Stroke, Vascular deathSignificantly increased of bleeding events in the combination treatment of clopidogre
19、l plus aspirinPrimary Safety RR(95CI) p valueSevere bleeding 1.25(0.97-1.61) 0.09Moderate bleeding 1.62(1.27-2.10) 0.00125%62%NATURE REVIEWS - DRUG DISCOVERY VOLUME 2; OCTOBER 2003; 1-15Inhibition of Platelets: By different PathwaysInhibition of Platelets: By different Pathways多中心,双盲,随机,双模拟,阿司匹林对照多中
20、心,双盲,随机,双模拟,阿司匹林对照设计设计:spsCCilostazol StrokePrevention Study 年龄:年龄:18-75 卒中发病卒中发病1-6个月个月 影像学影像学 (CT/MRI)确认脑梗死确认脑梗死 Modified Rankin Scale 4 没有严重的系统疾病没有严重的系统疾病 填写知情同意书填写知情同意书spsCCilostazol StrokePrevention Study研究设计研究设计spsCCilostazol StrokePrevention Study主要终结指标主要终结指标次要终结指标次要终结指标 安全性安全性:卒中复发(梗死,出血,蛛网膜
21、下腔出血卒中复发(梗死,出血,蛛网膜下腔出血MRI 显示新的梗死显示新的梗死血管死亡血管死亡MITIAs血管事件血管事件: PAD, PE, DVT, etc其他事件死亡其他事件死亡不良事件不良事件; 实验室化验异常实验室化验异常; ECG 异常异常spsCCilostazol StrokePreventionStudyR = Randomization1218months double-blind,double-dummy,treatmentcilostazol 100mg bid(n=360)ASA 100mg qd6th month12th month18th monthFollow-u
22、p finish3th month1st month16month after cerebral infarctionRTreatment start(n=360)0 dayScreening by PE/MRI/LAB.etcMRI主要终结指标累计主要终结指标累计 Kaplan-Meier Curve 主要终点指标Aspirin 5.27%Cilostazol 3.26%RR 38.1% 脑出血脑出血/脑梗死脑梗死Aspirin 33.3%Cilostazol 9.1% 123456 Period of No. Code Sex Age Drug Treatment Outcome 1365
23、40559437692538MMMMMM695755534266aspirinaspirincilostazolaspirinaspirinaspirinPVSRecoveringRecoveringRecoveringRecoveringDeathspsCCilostazol StrokePrevention Study871111117months症状性脑出血加无症状性核磁显症状性脑出血加无症状性核磁显示血肿示血肿 ASA 7 cases ( 5 symptomatic hemorrhage, 2 hemotoma in MRI) Cilostazol 1 cases p=0.0349No
展开阅读全文